Skip to main content
BLRX
NASDAQ Life Sciences

BioLineRx Sells 80% of APHEXDA Royalty to Soleus for $5.6M, Retires $3M of Kreos Debt

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$1.03
Mkt Cap
$9.169M
52W Low
$1.11
52W High
$3.95
52W Position info
7.2% below low
Off High info
74% below high
Rel. Volume info
1.8× avg
Market data snapshot near publication time

BLRX is trading near its 52-week low of $1.11 (7.2% below the low) on elevated volume (1.8× avg).

Summary

BioLineRx agreed to sell 80% of its APHEXDA royalty to a Soleus Capital affiliate for $5.6 million in non-dilutive cash, with $3.0 million of the proceeds prepaying Kreos debt and eliminating a $4.0 million minimum cash covenant. The deal is expected to close on or about November 30, 2026.


Key Events · Financing and Capital Events · BLRX

  • Royalty Sale to Soleus for $5.6M

    BioLineRx will sell 80% of its APHEXDA royalty receipts to SCOF Motixafortide Holdings, a Soleus Capital affiliate, for a one-time $5.6 million, less up to $100,000 of purchaser expenses.

  • 14.4% Royalty Transferred, 3.6% Kept

    Against the 18% royalty rate under the Ayrmid license, the sold 80% interest equals a 14.4% royalty on APHEXDA net sales, while the retained 20% equals 3.6% and covers the royalty owed upstream to Biokine. All future commercial milestone payments stay with BioLineRx.

  • Kreos Loan Cut, Cash Covenant Gone

    At closing BioLineRx prepays $3.0 million to Kreos, leaving about $2.0 million outstanding on a new repayment schedule and eliminating the $4.0 million minimum cash balance covenant.

  • Closing Targeted for November 30, 2026

    The transaction needs Ayrmid's consent to the sale and direct remittance, plus customary closing conditions; either party can terminate if closing has not occurred by February 1, 2027.


Analysis · BLRX · Life Sciences

With the stock near its 52-week low and a going-concern warning already on the record from the Q2 filing, $5.6 million of non-dilutive cash carries more weight than the headline size implies. BioLineRx is giving up 80% of its 18% APHEXDA royalty — a 14.4% royalty on net sales — while keeping the 3.6% slice that funds its obligation to Biokine, along with all future commercial milestones. Roughly $3.0 million of the proceeds goes straight to Kreos, cutting the loan to about $2.0 million and, more importantly, eliminating the $4.0 million minimum cash covenant that had constrained how low the balance sheet could run. After the ~$0.4 million Chardan fee and up to $0.1 million of purchaser expenses, the net cash retained is modest; the covenant relief and the retained milestone rights are the real prize. Closing is expected on or about November 30, 2026 and still depends on Ayrmid's consent and customary conditions.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BLRX was trading at $1.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.2M. The 52-week trading range was $1.11 to $3.95. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BLRX - Latest Insights

BLRX
Oct 02, 2026, 5:00 PM EDT
Filing Type: 424B3
Importance Score:
7
Price at Filing: $2.37
Real-time Price: $1.07 info
Change: -$1.30 (-55%) info
Market Cap: $9.169M info
BLRX
Sep 10, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $2.22
Real-time Price: $1.07 info
Change: -$1.15 (-52%) info
Market Cap: $9.169M info
BLRX
Aug 31, 2026, 11:19 AM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $2.74
Real-time Price: $1.07 info
Change: -$1.67 (-61%) info
Market Cap: $9.169M info
BLRX
Aug 31, 2026, 10:23 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $2.69
Real-time Price: $1.07 info
Change: -$1.62 (-60%) info
Market Cap: $9.169M info
BLRX
Aug 31, 2026, 7:15 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $2.73
Real-time Price: $1.07 info
Change: -$1.66 (-61%) info
Market Cap: $9.169M info